Bristol Takes $1.8B Hit, Ditches Hepatitis C Drug After Death
Bristol-Myers Squibb Co. on Friday said it's taking a $1.8 billion charge because of the previous day's abandonment of its hepatitis C treatment that was linked to severe side effects after...To view the full article, register now.
Already a subscriber? Click here to view full article